As FDA Advisers Grow Comfortable With EUAs, Harder Decisions On J&J’s Vaccine Fall To States, Individuals

 
• By Sarah Karlin-Smith

J&J’s COVID-19 vaccine sails through its US FDA advisory panel, but that just means the subpopulation efficacy questions need to be wrestled with by other public health space, as CDC and the states must figure out the best way to distribute multiple vaccines with differing efficacy profiles, regimens and storage requirements.

rugyby player kicking ball
FDA's VRBPAC punted the more challenging vaccine decisions to CDC's advisory panel • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers